Medical device company Merit Medical Systems (NASDAQ: MMSI) beat Wall Street’s revenue expectations in Q3 2026, with sales up 8.4% year on year to $416.2 million. The company expects the full year’s revenue to be around $1.64 billion, close to analysts’ estimates. Its non-GAAP profit of $1.12 per share was 7.8% above analysts’ consensus estimates.

Is now the time to buy MMSI? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

Merit Medical Systems delivered revenue and non-GAAP profit above Wall Street expectations in Q3, with management attributing results to broad-based organic growth across both foundational and therapeutic product categories. CEO Martha Aronson highlighted strong performance in the U.S. and ongoing demand for foundational and therapeutic products, underscoring balanced expansion. The company also benefited from improved operating leverage, with year-over-year margin gains despite some gross margin pressure from raw materials and freight costs. Management called out increased demand for oncology and endoscopy platforms as key drivers of the quarter.

Looking ahead, management’s updated guidance is supported by expectations for mid-single digit growth in foundational products and low double-digit gains in therapeutic products. The integration of recent acquisitions, such as View Point Medical and Solo Pace, remains a strategic priority, with leadership focused on leveraging these assets for future growth. CEO Martha Aronson stated the company is finalizing a multi-year strategic plan, including new product pipeline investments and operational improvements. The team also acknowledged challenges in China but emphasized ongoing initiatives to adapt and invest in local production for future market resilience.

Key insights from management’s remarks

Management cited a combination of strong U.S. sales, successful product launches, and improved operating efficiency as primary contributors to the quarter’s performance, while also addressing competitive dynamics and global market shifts.

• Balanced product growth: Organic growth was attributed to both foundational (vascular intervention, access, and OEM platforms) and therapeutic (oncology, endoscopy, and OEM) segments, with each showing robust momentum.
• Oncology and endoscopy strength: The oncology platform, supported by the launch of the SCOUT MD device and integration of OneMark from the View Point acquisition, saw significant demand, especially at academic institutions. Endoscopy also benefited from positive clinical data for the EsophyX device, used to treat GERD (gastroesophageal reflux disease).
• Operational efficiency gains: Operating margin improvement was achieved despite softer gross margins, driven by disciplined control of operating expenses and investment in sales and marketing.
• Supply chain and inventory strategy: The company increased inventory levels in response to raw material shortages and geopolitical risks, with a focus on normalizing working capital in the coming quarters.
• Acquisition of Solo Pace: The recent acquisition expands Merit’s Cardiac Therapies platform, adding technologies for transcatheter heart valve procedures (TAVR), which management sees as a growth market given the increasing adoption of minimally invasive cardiac interventions.

Drivers of future performance

Merit Medical’s outlook centers on continued product innovation, integration of recent acquisitions, and targeted investment to drive both revenue and margin expansion.

• Integration of new technologies: Management expects the Solo Pace and View Point Medical acquisitions to support growth in cardiac therapies and oncology, respectively, by expanding the product portfolio and leveraging Merit’s commercial capabilities.
• Ongoing margin discipline: The company plans further operating margin gains through operational efficiency, tighter inventory controls, and working capital improvements, while monitoring potential headwinds from raw material costs and tariffs.
• Market adaptation strategies: Leadership is actively responding to regulatory and competitive changes in international markets, particularly China, by investing in local manufacturing and diversifying geographic revenue streams to mitigate risk from government pricing pressures and local content requirements.

Catalysts in upcoming quarters

In the coming quarters, the StockStory team will watch (1) execution of the Solo Pace and View Point Medical integrations and their impact on the cardiac and oncology platforms, (2) the company’s ability to maintain margin discipline while normalizing inventory and adapting to supply chain headwinds, and (3) progress on localizing production and navigating regulatory challenges in China. The upcoming investor event in February will also be a key milestone, as management unveils its multi-year strategic plan and financial targets.

Merit Medical Systems currently trades at $87.20, down from $93.39 just before the earnings. Is there an opportunity in the stock? The answer lies in our full research report (it’s free).

Now could be the perfect time to invest in these stocks

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.